13. THIS ITEM ONLY APPLIES TO MODIFICATION OFCONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

EX-10.3 4 d230901dex103.htm MODIFICATION NO. P00005 TO CONTRACT NUMBER W9113M-10-0056 Modification No. P00005 to Contract Number W9113M-10-0056

Exhibit 10.3

 

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT    1. CONTRACT ID CODE

V

   PAGE OF PAGES
      1    3

2. AMENDMENT/MODIFICATION NO.

 

P00005

 

3. EFFECTIVE DATE

 

08/15/2011

  

4. REQUISITION/PURCHASE REQ. NO.

 

see schedule

  5. PROJECT NO. (If applicable)

6. ISSUED BY         CODE

  W911QY    7. ADMINISTERED BY (If other than Item 6) CODE    S4801A

 

NATICK CONTRACTING DIVISION

64 Thomas Johnson Drive

Frederick MD ###-###-####

  

 

DCMA

DCMA-SEATTLE

CORPORATE CAMPUS EAST III

3009 112TH AVE. NE STE200

BELLEVUE WA 98004-8019

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

 

AVI BIOPHARMA INC

4575 SW RESEARCH WAY STE 200

CORVALLIS OR ###-###-####

   (X)    9A. AMENDMENT OF SOLICIATION NO.
  

 

¨

  
     

9B. DATED (SEE ITEM 11)

 

   x   

10A. MODIFICATION OF CONTRACT/ORDER NO.

 

W9113M-10-C-0056

       

10B. Dated (SEE ITEM 13)

 

Jul 14, 2010

CODE 49WU1

  

FACILITY CODE

                           
11.THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
¨ The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers    ¨ is extended,    ¨ is not extended.

 

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

 

(a) By completing items 8 and 15, and returning             copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;

 

or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment your desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

 

12. ACCOUNTING AND APPROPIRATION DATA                 (If required)

 

See SCHEDULE

13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS.

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

CHECK ONE

   A. THIS CHANGE ORDER IS ISSUED PURSUANT TO:     (Specify authority)             THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

¨

  

¨

   B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES     (such as changes in paying office, appropriation date, etc. ) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

x

  

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PRUSUANT TO AUTHORITY OF:

 

Mutual Agreement of Both Parties

x

   D. OTHER    (Specify type of modification and authority)

E. IMPORTANT:

   Contractor     ¨ is not,         x is required to sign this document and return             1             copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION ( Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

 

See Attached Summary of Changes.

 

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print)

Chris Garabedian

President and CEO

  

16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

Sandra J. O’Connell

 

Contracting Officer

15B. CONTRACTOR/OPERATOR

 

/s/ Chris Garabedian                            

(Signature of person authorized to sign)

  

15C. DATE SIGNED

 

9/23/11

  

16B. UNITED STATES OF AMERICA

 

/s/ Sandra J. O’Connell                        

(Signature of Contracting Officer)

  

16C. DATE SIGNED

 

9/26/11

NSN 7540-01-152-8070

Previous edition unusable

  

STANDARD FORM 30 (Rev. 10-83)

Prescribed by GSA FAR (48 CFR) 53.243

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.


 

W9113M-10-C0056

(soconnell 13438)

Page 2 of 3

SECTION SF 30 BLOCK 14 CONTINUATION PAGE

SUMMARY OF CHANGES

 

  A. The purpose of this modification is to move studies/tasks originally planned in Option CLINs 0002 and 0006 into CLINs 0001 and 0005 thereby affecting the total cost and schedule of this contract as shown below.

 

  1. SECTION A—SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by $46,142,707.00 from $80,396,827.37 to $126,539,534.37.

 

  2. SECTION B—SUPPLIES OR SERVICES AND PRICES

CLIN 0001

The target cost has increased by $[†] from $[†] to $[†].

The target profit/fee has increased by $[†] from $[†] to $[†].

The minimum profit fee has increased by $[†] from $[†] to $[†].

The maximum profit fee has increased by $[†] from $[†] to $[†].

The total cost of this line item has increased by $[†] from $[†] to $[†].

CLIN 0002

The target cost has decreased by $[†] from $[†] to $[†].

The target profit/fee has decreased by $[†] from $[†] to $[†].

The minimum profit fee has decreased by $[†] from $[†] to $[†].

The maximum profit fee has decreased by $[†] from $[†] to $[†].

The total cost of this line item has decreased by $[†] from $[†] to $[†].

CLIN 0005

The target cost has increased by $[†] from $[†] to $[†].

The target profit/fee has increased by $[†] from $[†] to $[†].

The minimum profit fee has increased by $[†] from $[†] to $[†].

The maximum profit fee has increased by $[†] from $[†] to $[†].

The total cost of this line item has increased by $[†] from $[†] to $[†].

CLIN 0006

The target cost has decreased by $[†] from $[†] to $[†].

The target profit/fee has decreased by $[†] from $[†] to $[†].

The minimum profit fee has decreased by $[†] from $[†] to $[†].

The maximum profit fee has decreased by $[†] from $[†] to $[†].

The total cost of this line item has decreased by $[†] from $[†] to $[†].

 

  3. SECTION F - DELIVERIES OR PERFORMANCE

The following Delivery Schedule item for CLIN 0001 has been changed from:

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.


 

W9113M-10-C0056

(soconnell 13438)

Page 3 of 3

DELIVERY DATE

     QUANTITY       SHIP TO ADDRESS      UIC   

 

25-MAR-2012

     

 

N/A

FOB: Destination

  

To:

 

DELIVERY DATE    QUANTITY    SHIP TO ADDRESS    UIC
18-APR-2013       N/A FOB: Destination   

The following Delivery Schedule item for CLIN 0005 has been changed from:

 

DELIVERY DATE    QUANTITY    SHIP TO ADDRESS    UIC
01-APR-2012       N/A FOB: Destination   

To:

 

DELIVERY DATE    QUANTITY    SHIP TO ADDRESS    UIC
10-MAY-2013       N/A FOB: Destination   

4. SECTION J — LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

Attachment No. 1 Contractor’s Statement of Work — Ebola Virus, Dated 3/11/10 and Attachment No. 2 Contractor’s Statement of Work — Marburg Virus, Dated 3/11/10 are replaced in their entirety with the Attachments to this modification.

 

  B. An Integrated Baseline Review (IBR) will be held within 3 months of the date of this modification. At that time the Performance Measurement Baseline (PMB) will be approved by the Government for the changed efforts of CLINs 0001; 0002, 0005 and 0006. A modification will be executed upon acceptance of the PMB, and will incorporate any approved changes to the budget that are required.

 

  C. As a result of this modification all other terms and conditions of this contract are unchanged and remain in full force and effect.

(End of Summary of Changes)

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Appendix B: Revised Statement of Work

3.0 CONTRACT

AVI BioPharma (AVI) Statement of Work for AVI-6002 as an effective therapeutic for ebolavirus:

3.2 CLIN0001 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    1
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.2.2.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.2.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2.2.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    2
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.2.3 [†]: [†]

[†]

Period of Work: [†].

Deliverable: [†].

3.2.3.1 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.2.3.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.3.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.3.1.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    3
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

[†]

Period of Work: [†].

Deliverable: [†]

3.2.3.1.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.3.2.1 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.2.3.2.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    4
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†]

3.2.3.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.3.2.4 [†]: [†]

Period of Work: [†]

Deliverable: [†]

3.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.4.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.1.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    5
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.2.4.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.1.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.1.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    6
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.2.4.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    7
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.2.4.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.3.2 [†]: [†]

Period of Work: [†]

Deliverable: [†]

3.2.4.3.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.3.4 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    8
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†]

3.2.4.3.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5 [†]: [†]

Period of Work: [†]

Deliverable: [†]

3.2.5.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    9
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.2.5.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.8 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    10
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†]

3.2.5.9 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.2.6 [†]: [†]

[†]

Period of Work: [†].

Deliverable: [†].

3.2.6.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.6.2 [†]: [†]

Period of Work: [†].

Deliverable:. [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    11
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.2.6.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.7 [†]: [†]

[†]

Period of Work: [†].

Deliverable: [†].

3.2.7.1 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.2.7.2 Finance and EVMS: [†].

Period of Work: [†].

Deliverable: [†].

3.2.7.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.7.4 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    12
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.3 [†]: [†]

[†]

Period of Work: [†].

Deliverable: [†].

3.3.1 [†]:[†]

[†]

Period of Work: [†].

Deliverable: [†]

3.3.1.1 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    13
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†]

3.3.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

[†]

3.3.2.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    14
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.3.2.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.1.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    15
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.3.2.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    16
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.

   
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.3.2.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    17
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.3.2.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.3.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    18
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.3.4. [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.4.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.4.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.4.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.4.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.4.5 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    19
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.3.4.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.5 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.5.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    20
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†]

3.3.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.5.3 [†]: [†]

Period of Work: [†]

Deliverable: [†]

3.3.6 [†]: [†]

Period of Work: [†].

Deliverable: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    21
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.3.6.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.6.2 [†]: [†]

Periods of Work: [†]

Deliverable: [†]

3.3.6.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.7 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    22
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.3.7.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.7.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

CLIN0001 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.8. [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.8.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    23
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.3.8.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.8.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.8.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.8.5 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

`    Use or disclosure of data contained on this sheet is subject to the    24
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.3.9 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.9.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.9.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.9.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.9.4 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    25
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.3.9.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.10 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.10.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.10.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.11 [†]: [†]

Period of Work: [†]

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    26
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.3.11.1 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.3.11.2 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.3.11.3 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.3.11.4: [†]. [†]

Period of Work: [†]

Deliverable: [†]

3.3.11.5 [†]. [†]

Period of Work: [†]

Deliverable: [†].

3.3.11.6 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    27
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.3.11.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.11.8 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.11.9 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.11.10 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.3.12 [†]. [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    28
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.3.12.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.12.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.12.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    29
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.3.12.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.13 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.13.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.13.2 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    30
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.3.13.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.13.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.13.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.14. [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.14.1 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    31
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.3.14.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.14.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.15 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.15.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.15.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.15.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    32
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.3.16.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    33
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.3.16.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.17.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.17.1.1 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    34
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†]

3.3.17.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.17.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.17.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.17.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.17.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.17.2.4 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    35
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.3.17.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.17.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4 CLIN0002: [†]

Period of Work: [†].

Deliverable: [†].

3.4.1: [†]. [†]

Period of Work: [†].

Deliverable: [†].

3.4.1.1: [†]. [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    36
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.4.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.1.3: [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    37
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.4.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    38
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.4.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.1.1 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.4.3.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.1.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    39
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.4.3.1.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.2.1 [†].[†]

Period of Work: [†].

Deliverable: [†].

3.4.3.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.2.3 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    40
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.4.3.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.4: [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.4.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.4.2 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    41
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.4.4.3 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.4.4.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.4.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.4.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.4.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.5 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    42
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.4.5.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.5.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.5.3 [†]: [†]

Period of Work: [†]

Deliverable: [†]

3.4.5.4 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    43
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.4.6 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.6.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.6.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.6.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.6.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    44
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.4.6.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.6.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.6.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.6.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.7.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    45
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.4.7.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.7.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.7.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.2 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    46
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.4.8.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.5 [†]: [†].

3.4.8.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.8 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.8.9 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    47
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.4.9 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.9.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    48
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.4.9.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.9.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.4 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    49
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†]

3.4.9.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.10 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.10.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.10.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.10.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    50
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.4.11 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.11.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.11.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.11.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    51
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.4.11.4 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.4.12 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.12.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.12.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.13 [†]: [†]

3.4.14 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    52
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†]

3.4.14.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.1.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.2 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    53
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.4.14.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    54
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.4.14.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.14.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.14.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.15 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    55
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.4.15.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.15.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.15.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.15.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.5 CLIN0003: [†]

Period of Work: [†].

Deliverable: [†].

3.5.1 [†]: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    56
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.5.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.5.3.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.5.3.1.2 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.5.3.1.3 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    57
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [].

3.5.3.1.4 [†]: [†]

Period of Work: [†].

Deliverable: [].

3.5.3.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    58
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [].

Deliverable: [].

3.5.3.2.1 [†]: [†]

Period of Work: [].

Deliverable: [†].

3.5.3.2.2 [†]: [†]

Period of Work: [].

Deliverable: [].

3.5.3.2.3 [†]: [†]

Period of Work: [].

Deliverable: [].

3.5.3.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    59
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.5.3.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.3.2 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.5.3.4 [†]: [†].

Period of Work: [†].

Deliverable: [†]

3.5.3.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.4 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    60
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.5.4.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.4.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.4.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.4.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.5.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.5.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.6.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    61
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3. 5.6.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.6.3 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.5.6.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6 CLIN0004: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    62
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.6.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    63
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.6.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    64
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

3.6.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.3.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.3.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.4.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    65
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

3.6.4.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.5.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.6 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    66
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.6.6.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.6.2 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.6.6.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.7 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    67
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Deliverable: [†].

3.6.7.1 Program Management: [†].

Period of Work: [†].

Deliverable: [†].

3.6.7.2 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.6.7.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.7.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6.8 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.8.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.8.2 [†]: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    68
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.    
HFV-ZEBOV   Final Statement of Work  
  12 August 2011  

 

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    69
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Appendix B: Revised Statement of Work

3.0 CONTRACT

AVI BioPharma (AVI) Statement of Work for AVI-6003 as an effective therapeutic for Marburgvirus:

3.2 CLIN0005 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    1
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.2.2.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.2.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.2.2.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    2
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.2.3 [†]: [†]

        [†]

Period of Work: [†].

Deliverable: [†].

3.2.3.1 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.2.3.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.3.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.3.1.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    3
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

[†]

Period of Work: [†].

Deliverable: [†]

3.2.3.1.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.3.2.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    4
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†]

Deliverable: [†].

3.2.3.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.3.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.3.2.3.1 [†]: [†]

Period of Work: [†]

Deliverable: [†]

3.2.3.2.4 [†]: [†]

Period of Work: [†]

Deliverable: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    5
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.4.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.1.4 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    6
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.2.4.1.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    7
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.2.4.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.3.1 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    8
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.2.4.3.2 [†]: [†]

Period of Work: [†]

Deliverable: [†]

3.2.4.3.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.4.3.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.4.3.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    9
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†]

Deliverable: [†]

3.2.5.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.5 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    10
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.2.5.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.2.5.8 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.5.9 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.2.6 [†]: [†]

3.2.6.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    11
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

3.2.7 [†]: [†]

[†]

Period of Work: [†].

Deliverable: [†].

3.2.7.1 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.2.7.2 Finance and EVMS: [†].

Period of Work: [†].

Deliverable: [†].

3.2.7.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.2.7.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    12
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3 [†]: [†]

[†]

Period of Work: [†].

Deliverable: [†].

3.3.1 [†]: [†]

[†]

Period of Work: [†].

Deliverable: [†]

3.3.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    13
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

[†]

3.3.2.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.1.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    14
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.3.2.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.1.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    15
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.3.2.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.2.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    16
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.3.2.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.2.5 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    17
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†]

3.3.2.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    18
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.4. [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.4.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.4.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.4.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.4.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    19
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.4.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.4.6 [†]:

[†]

Period of Work: [†].

Deliverable: [†].

3.3.5 [†]: [†]

Period of Work: [†].

Deliverable: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    20
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.5.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.5.3 [†]: [†]

Period of Work: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    21
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†]

3.3.6 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.6.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.6.2 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    22
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†]

3.3.6.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.7.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.7.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

CLIN0005 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    23
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.8. [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.8.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.8.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.8.3 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    24
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.3.8.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.8.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.9 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.9.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    25
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.9.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.9.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.9.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.9.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.10 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    26
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.3.10.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.10.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.11 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.3.11.1 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.3.11.2 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.3.11.3 [†]: [†]

Period of Work: [†]

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    27
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.11.4: [†]. [†]

Period of Work: [†]

Deliverable: [†]

3.3.11.5 [†]. [†]

Period of Work: [†]

Deliverable: [†].

3.3.11.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.11.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.11.8 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    28
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.3.11.9 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.11.10 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.3.12 [†]. [†]

Period of Work: [†].

Deliverable: [†].

3.3.12.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    29
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†]

3.3.12.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.12.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.12.4 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    30
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.3.13 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.13.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]. 

3.3.13.2 [†]: [†]

Period of Work: [†].

Deliverable: [†] 

3.3.13.3 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    31
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†]. 

3.3.13.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.13.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.14. [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.14.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.14.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    32
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.14.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.15 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.15.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.15.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.15.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.1 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    33
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.3.16.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    34
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.16.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.16.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.17.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.17.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.3.17.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    35
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.17.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.17.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.17.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.17.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.17.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.3.17.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    36
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.3.17.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4 CLIN0006: [†]

Period of Work: [†].

Deliverable: [†].

3.4.1: [†]. [†]

Period of Work: [†].

Deliverable: [†].

3.4.1.1: [†]. [†]

Period of Work: [†].

Deliverable: [†].

3.4.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    37
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.4.1.3: [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.2.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    38
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.4.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.3.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    39
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.4.3.1.1 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.4.3.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.1.4 [†]: [†]

Period of Work: [†].

Deliverable: []

3.4.3.1.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    40
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.4.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.2.1 [†]. [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.3.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    41
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.4.3.4: [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.4.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.4.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    42
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.4.4.3 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.4.4.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.4.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.4.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.4.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.5 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    43
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.4.5.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.5.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.5.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.5.4 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    44
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.4.6 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.6.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.6.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.6.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.6.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    45
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.4.6.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.6.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.6.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.6.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.7 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    46
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.4.7.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.7.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.7.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.7.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.1 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    47
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.4.8.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.5 [†]: [†].

3.4.8.6 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.8.8 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    48
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†]

3.4.8.9 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.9.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.1.2 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    49
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.4.9.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.9.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.9.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    50
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.4.9.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.9.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.10 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.10.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    51
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.4.10.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.10.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.11 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.11.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    52
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.4.11.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.11.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.11.4 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.4.12 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.12.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.12.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    53
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.4.13 [†]: [†]

3.4.14 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.14.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.1.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    54
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.4.14.1.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    55
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.4.14.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.14.3.2 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    56
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†]

3.4.14.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.4.14.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.15 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.15.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    57
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.4.15.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.15.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.4.15.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.5 CLIN0007: [†]

Period of Work: [†].

Deliverable: [†].

3.5.1 [†]: [†].

3.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.2.1 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    58
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.5.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.5.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.5.3.1.1 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    59
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†]

3.5.3.1.2 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.5.3.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.1.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.2.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    60
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.5.3.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.2.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.2.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.2.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.3 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    61
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.5.3.3.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.3.3.2 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.5.3.4 [†]: [†].

Period of Work: [†].

Deliverable: [†]

3.5.3.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.4.1 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    62
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.5.4.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.4.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.4.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.5.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.5.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.6 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    63
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.5.6.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3. 5.6.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.5.6.3 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.5.6.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6 CLIN0008: [†]

Period of Work: [†].

Deliverable: [†].

3.6.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    64
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.6.1.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.1.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.1.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.2 [†]:         [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    65
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.6.2.1 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6.2.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.3 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6.3.1 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    66
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.6.3.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.3.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.3.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6.4 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.4.1 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    67
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.6.4.2 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6.5 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.5.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.5.2 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.6 [†]: [†]

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    68
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Period of Work: [†].

Deliverable: [†].

3.6.6.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.6.2 [†]: [†]

Period of Work: [†]

Deliverable: [†].

3.6.6.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    69
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

3.6.7 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.7.1 Program Management: [†].

Period of Work: [†].

Deliverable: [†].

3.6.7.2 [†]: [†].

Period of Work: [†].

Deliverable: [†].

3.6.7.3 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.7.4 [†]: [†]

Period of Work: [†].

Deliverable: [†]

3.6.8 [†]: [†]

Period of Work: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    70
W9113M-09-R-0008    restriction on the title page of this proposal.   


AVI BioPharma, Inc.      
HFV-MARV    Final Change Proposal: Statement of Work   
   16 September 2011   

 

Deliverable: [†].

3.6.8.1 [†]: [†]

Period of Work: [†].

Deliverable: [†].

3.6.8.2 [†]: [†].

Period of Work: [†].

Deliverable: [†].

 

DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

 

   Use or disclosure of data contained on this sheet is subject to the    71
W9113M-09-R-0008    restriction on the title page of this proposal.